Workshop to identify critical windows of exposure for children's health: Cardiovascular and endocrine work group summary

被引：26

作者：

Barr, M

DeSesso, JM

Lau, CS

Osmond, C

Ozanne, SE

Sadler, TW

Simmons, RA

Sonawane, BR

机构：

[1] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Obstet, Ann Arbor, MI 48109 USA

[4] Mitretek Syst, Mclean, VA USA

[5] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA

[6] Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO9 4XY, Hants, England

[7] Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England

[8] Univ N Carolina, UNC Birth Defects Ctr, Chapel Hill, NC USA

[9] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA

[10] US EPA, Natl Ctr Environm Assessment, Effects Idenificat & Characterizat Grp, Washington, DC 20460 USA

来源：

ENVIRONMENTAL HEALTH PERSPECTIVES | 2000年 / 108卷

关键词：

developmental toxicity; endocrine; heart; teratogen;

D O I：

10.2307/3454548

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

The work group on cardiovascular and endocrine effects was asked to review the current state of knowledge about children's windows of vulnerability to developmental toxicants and to recommend how that information may be used to improve risk assessment and public health. We considered differences between structural defects, where periods of vulnerability are rather well defined, and functional defects, where periods of vulnerability are quite elusive.

引用

页码：569 / 571

页数：3

共 20 条

[1]

Adams GR, 1999, AM J PHYSIOL-REG I, V276, pR954

[2]

[Anonymous], HDB TERATOLOGY

[3] Growth as a manifestation of teratogenesis: Lessons from human fetal pathology [J].

Barr, M .

REPRODUCTIVE TOXICOLOGY, 1997, 11 (04) :583-587

[4]

Barr M, 1998, AM J MED GENET, V79, P249, DOI 10.1002/(SICI)1096-8628(19981002)79:4<249::AID-AJMG4>3.0.CO

[5]

2-H

[6]

Barr M., 1998, Teratology, V57, P197

[7]

BARR M, UNPUB

[8]

BARR M, 1996, HDB EXPT PHARM DRUG, P265

[9]

Clark EB., 1987, GENETICS CARDIOVASCU, P3

[10]

FERENCZ C, 1997, GENETIC ENV RISK FAC, P359

← 1 2 →